<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="keywords" content="" />
<meta name="description" content="" />
<meta http-equiv="content-type" content="text/html; charset=utf-8" />
<title>Neural Picks - Free AI Powered Stock Market Advice</title>
<link href="//fonts.googleapis.com/css?family=Abel|Arvo" rel="stylesheet" type="text/css" />
<link href="style.css" rel="stylesheet" type="text/css" media="screen" />
</head>
<body>
<div id="wrapper">
<div id="header">
<div id="logo">
<h1><a href="#">neural picks</a></h1>
</div>
</div>
<div id="about">
<h2 class="title">Updated on: 05/20/2021, 19:32:57</h2>
<p><img src="images/pics01.jpg" alt="" width="225" height="225" class="alignleft" /><strong>Disclaimer:</strong> This is a project for fun and none of the stock recommendations here should be executed using real money. I am not a professional stock advisor. All trading decisions and associated risks are your own, and I do not take responsibility for any losses.<br /><br /><strong>About:</strong> Stocks are ranked using Deep Learning according to performance on different quantitative and qualitative metrics. Stocks higher up on the list are predicted to have the highest returns over the next 3 weeks, but daily price swings can vary significantly. Forming a portfolio of multiple stocks can reduce daily risks.<br /><br /><strong>Contribute:</strong> Our mission is to further democratize finance by organizing high-quality publicly available information into actionable rankings. This information is free, however donations are highly appreciated at SegWit Bitcoin Wallet Address: bc1qxv7drjce5hx9l6eyht6ejtx2rex36an78fp82t</p>
<!-- AddToAny BEGIN -->
<div class="a2a_kit a2a_kit_size_32 a2a_default_style">
<a class="a2a_dd" href="https://www.addtoany.com/share"></a>
<a class="a2a_button_facebook"></a>
<a class="a2a_button_twitter"></a>
<a class="a2a_button_email"></a>
<a class="a2a_button_reddit"></a>
</div>
<script async src="https://static.addtoany.com/menu/page.js"></script>
<!-- AddToAny END --></div>
<div id="page">
<div id="content"><div class="post"><h2 class="title"><a href="#">MUR</a></h2><p class="meta">Rank #1 | $20.99 / share</p><div class="entry">       <p>Murphy Oil Corporation operates as an oil and natural gas exploration and production company in the United States, Canada, and internationally. It explores for and produces crude oil, natural gas, and natural gas liquids. The company was formerly known as Murphy Corporation and changed its name to Murphy Oil Corporation in 1964. Murphy Oil Corporation was incorporated in 1950 and is headquartered in El Dorado, Arkansas.</p>       <ul>
       <li>Robinhood Adjusted Rating: 26.667%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 43.307%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>Fair Stock Price Estimate: $23.01 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -20.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">TTD</a></h2><p class="meta">Rank #2 | $543.3 / share</p><div class="entry">       <p>The Trade Desk, Inc. operates as a technology company in the United States and internationally. The company operates a self-service cloud-based platform that allows buyers to create, manage, and optimize data-driven digital advertising campaigns in various advertising formats, including display, video, audio, native and social, and on various devices, such as computers, mobile devices, and connected TV. It also provides data and other value-added services, as well as platform features. The company serves advertising agencies and other service providers for advertisers. The Trade Desk, Inc. was founded in 2009 and is headquartered in Ventura, California.</p>       <ul>
       <li>Suggested By Multiple Sources</li>
       <li>Robinhood Adjusted Rating: 59.701%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 64.375%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 69.64%</li>
       <li>Social Media Sentiment: 80.046%</li>
       <li>Recent Death Cross</li>
       <li>Fair Stock Price Estimate: $552.23 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -8.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">NBIX</a></h2><p class="meta">Rank #3 | $94.37 / share</p><div class="entry">       <p>Neurocrine Biosciences, Inc., a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis. Its product candidates in clinical development include elagolix that has completed Phase III clinical trial for uterine fibroids; opicapone, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company's products under development include NBIb-1817, an AADC gene replacement therapy, which is in Phase II clinical trial for the treatment of Parkinson's disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients with SCN8A-DEE, as well as other indications, such as adult focal epilepsy; ACT-709478, an orally active and brain penetrating T-type calcium channel blocker for use in certain forms of generalized epilepsy; and VMAT2 inhibitor for the treatment of various neurology and/or psychiatry disorders. Neurocrine Biosciences, Inc. has collaborations and agreements with AbbVie Inc.; BIAL ? Portela & Ca, S.A.; Voyager Therapeutics, Inc.; Xenon Pharmaceuticals Inc.; Mitsubishi Tanabe Pharma Corporation; Idorsia Pharmaceuticals Ltd; and Takeda Pharmaceutical Company Limited. The company was founded in 1992 and is headquartered in San Diego, California.</p>       <ul>
       <li>Robinhood Adjusted Rating: 73.913%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 83.019%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>Social Media Sentiment: 50.048%</li>
       <li>Fair Stock Price Estimate: $102.98 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -12.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">EXTR</a></h2><p class="meta">Rank #4 | $11.74 / share</p><div class="entry">       <p>Extreme Networks, Inc. provides software-driven networking solutions for enterprise, data center, and service provider customers worldwide. It designs, develops, and manufactures wired and wireless network infrastructure equipment; and develops software for network management, policy, analytics, security, and access controls. The company offers ExtremeSwitching portfolio that includes access edge products that offer physical presentations along with options to deliver Ethernet or convergence-friendly Power-over-Ethernet (POE), including high-power universal POE; aggregation/core switches designed to address aggregation, top-of-rack, and campus core environments; and wireless access point products. It also provides ExtremeNAC, a network access control solution that allows the enterprises to unify the security of their wired and wireless networks with visibility and control over users, devices, and applications; and ExtremeAnalytics, a network-powered application analytics and optimization solution, which captures, aggregates, analyses, correlates, and reports network data that enables in decision making and enhancing business performance. In addition, the company offers ExtremeCloud, a wired and wireless cloud network management solution, which offers visibility and control over users, devices, and applications; ExtremeRouting, a cloud-managed access across distributed environment that provides throughput, application-aware traffic shaping and monitoring, end-to-end service, and link prioritization; and an open northbound API for customized integrations to key enterprise platforms. It markets and sells its products through distributors, resellers, and field sales organizations to enterprises and organizations in the education, healthcare, retail, manufacturing, hospitality, transportation and logistics, government agencies, private cloud data centers, universities, and stadiums. Extreme Networks, Inc. was founded in 1996 and is headquartered in San Jose, California.</p>       <ul>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 77.273%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $13.36 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -40.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">FB</a></h2><p class="meta">Rank #5 | $318.61 / share</p><div class="entry">       <p>Facebook, Inc. develops products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, and in-home devices worldwide. The company's products include Facebook that enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers; Instagram, a community for sharing photos, videos, and private messages; Messenger, a messaging application for people to connect with friends, family, groups, and businesses across platforms and devices; and WhatsApp, a messaging application that is used by people and businesses to communicate in a private way. It also provides Oculus, a hardware, software, and developer ecosystem, which allows people to come together and connect with each other through its Oculus virtual reality products. Facebook, Inc. was founded in 2004 and is headquartered in Menlo Park, California.</p>       <ul>
       <li>Robinhood Adjusted Rating: 87.31%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 92.628%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Social Media Sentiment: -87.402%</li>
       <li>Fair Stock Price Estimate: $324.71 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -84.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">CORT</a></h2><p class="meta">Rank #6 | $21.56 / share</p><div class="entry">       <p>Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator that is in Phase II for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.</p>       <ul>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Social Media Sentiment: 24.489%</li>
       <li>Fair Stock Price Estimate: $22.33 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -12.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">FLGT</a></h2><p class="meta">Rank #7 | $73.64 / share</p><div class="entry">       <p>Fulgent Genetics, Inc. operates as a technology company, which provides genetic testing and next generation sequencing solutions. The company is headquartered in Temple City, California and currently employs 123 full-time employees. The firm offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The firm has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. The firm's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers.</p>       <ul>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Social Media Sentiment: 53.701%</li>
       <li>Fair Stock Price Estimate: $77.56 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -80.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">MBIN</a></h2><p class="meta">Rank #8 | $43.74 / share</p><div class="entry">       <p>Merchants Bancorp (Indiana) is a bank holding company, which specializes in a multiple lines of business in banking and finance. The company is headquartered in Carmel, Indiana and currently employs 259 full-time employees. The Bank operate multiple lines of business with a focus on FHA multi-family housing and healthcare facility financing and servicing, mortgage warehouse financing, retail and correspondent residential mortgage banking, agricultural lending and traditional community banking. The Bank operates in three primary segments: Multi-family Mortgage Banking, Mortgage Warehousing, and Banking. The Multi-family Mortgage Banking segment originates and services government sponsored mortgages for multi-family and healthcare facilities. The Mortgage Warehousing segment funds agency eligible residential loans from origination or purchase to sale in the secondary market, as well as commercial loans to non-depository financial institutions. The Banking segment provides a wide range of financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage and other consumer loan products.</p>       <ul>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $50.0 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: 8.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">FVRR</a></h2><p class="meta">Rank #9 | $182.26 / share</p><div class="entry">       <p>Fiverr International Ltd. operates an online marketplace worldwide. Its platform enables sellers to sell their services and buyers to buy them. The company's platform includes approximately 300 categories in eight verticals, including graphic and design, digital marketing, writing and translation, video and animation, music and audio, programming and technology, business, and lifestyle. It also offer And.Co, a platform for online back office service to assist freelancers with invoicing, contracts and task management; Fiverr Learn, an online learning platform with original course content in categories such as graphic design, branding, digital marketing, and copywriting; and ClearVoice, a subscription based content marketing platform for medium to large businesses. Its buyers include businesses of various sizes, as well as sellers comprise a group of freelancers and small businesses. The company was founded in 2010 and is headquartered in Tel Aviv, Israel.</p>       <ul>
       <li>Robinhood Adjusted Rating: 68.571%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 82.946%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 79.46%</li>
       <li>Social Media Sentiment: -29.128%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">GMAB</a></h2><p class="meta">Rank #10 | $38.68 / share</p><div class="entry">       <p>Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company's products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has a commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and a strategic collaboration agreement with Tempus to advance various disease targets and biomarkers, as well as Rentschler Biopharma SE. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; and Tavotek Biotherapeutics and AbbVie. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.</p>       <ul>
       <li>Robinhood Adjusted Rating: 69.388%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 83.396%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">VICI</a></h2><p class="meta">Rank #11 | $31.2 / share</p><div class="entry">       <p>VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.</p>       <ul>
       <li>Robinhood Adjusted Rating: 91.892%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 93.827%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $31.79 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: 44.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">ATH</a></h2><p class="meta">Rank #12 | $62.19 / share</p><div class="entry">       <p>Athene Holding Ltd., a retirement services company, issues, reinsures, and acquires retirement savings products for individuals and institutions in the United States and Bermuda. The company provides annuity retirement solutions to its policyholders; and reinsures multi-year guaranteed annuities, fixed indexed annuities, traditional one-year guarantee fixed deferred annuities, immediate annuities, and institutional products. It also offers funding agreements and group annuities. The company was incorporated in 2008 and is headquartered in Pembroke, Bermuda.</p>       <ul>
       <li>Robinhood Adjusted Rating: 45.455%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 57.944%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $101.52 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: 8.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">VRTX</a></h2><p class="meta">Rank #13 | $216.61 / share</p><div class="entry">       <p>Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics. The company was founded in 1989 and is headquartered in Boston, Massachusetts.</p>       <ul>
       <li>Robinhood Adjusted Rating: 88.0%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 90.637%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Social Media Sentiment: 37.991%</li>
       <li>Fair Stock Price Estimate: $239.34 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -52.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">WCC</a></h2><p class="meta">Rank #14 | $103.91 / share</p><div class="entry">       <p>WESCO International, Inc. distributes electrical, industrial, and communications maintenance, repair, and operating (MRO) and original equipment manufacturers products and construction materials in North America and internationally. The company sells general supplies, such as wiring devices, fuses, terminals, connectors, boxes, enclosures, fittings, lugs, terminations, wraps, splicing and marking equipment, tools and testers, safety, personal protection, sealants, cutting tools, adhesives, consumables, fasteners, janitorial, and other MRO supplies; communication and metering devices, and racking systems; and solar modules, connectors, and storage batteries. It also distributes wires, cables, raceways, metallic and non-metallic conduits, and coupling and fittings; and communications and security products, including structured cabling systems, broadband products, low voltage specialty systems, specialty wire and cable products, equipment racks and cabinets, access controls, alarms, cameras, and paging and voice solutions. In addition, the company sells electrical distribution and controls comprising circuit breakers, transformers, switchboards, panel boards, metering products, and busway products; lamps, fixtures, ballasts, and lighting control products; and motor control devices, drives, relays, timers, pushbuttons, operator interfaces, switches, interconnects, programmable controllers, industrial computers and network, and surge and power protection products. Further, it provides supply chain management and logistics services; and value-added services in the areas of construction, e-commerce, energy and sustainability, engineering, production support, safety and security, supply chain optimization, training, and working capital. It serves industrial firms, electrical and data communications contractors, utilities, commercial organizations, institutions, and governmental entities. The company was founded in 1922 and is headquartered in Pittsburgh, Pennsylvania.</p>       <ul>
       <li>Robinhood Adjusted Rating: 80.0%</li>
       <li>Financial Modeling Prep Rating: 100.0%</li>
       <li>Finnhub Adjusted Rating: 81.061%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 79.46%</li>
       <li>Fair Stock Price Estimate: $92.08 (Stock is Overvalued)</li>
       <li>Insider Trading Transactions Rating: -48.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">SWAV</a></h2><p class="meta">Rank #15 | $168.87 / share</p><div class="entry">       <p>ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.</p>       <ul>
       <li>Financial Modeling Prep Rating: 0.0%</li>
       <li>Finnhub Adjusted Rating: 72.826%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Fair Stock Price Estimate: $170.35 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -76.0%</li>
       </ul>
</div></div><div class="post"><h2 class="title"><a href="#">OKTA</a></h2><p class="meta">Rank #16 | $234.03 / share</p><div class="entry">       <p>Okta, Inc. provides identity management platforms for enterprises, small and medium-sized businesses, universities, non-profits, and government agencies in the United States and internationally. The company offers Okta Identity Cloud, a platform that offers a suite of products to manage and secure identities, such as Universal Directory, a cloud-based system of record to store and secure user, application, and device profiles for an organization; and Single Sign-On that enables users to access their applications in the cloud or on-premise from various devices with a single entry of their user credentials. It also provides Adaptive Multi-Factor Authentication, a product that provides an additional layer of security for cloud, mobile, and Web applications, as well as for data; Lifecycle Management, which enables IT organizations or developers to manage a user's identity throughout its lifecycle; API Access Management that enables organizations to secure APIs; Advanced Server Access to secure cloud infrastructure; and Access Gateway that enables organizations to extend the Okta Identity Cloud from the cloud to their existing on-premise applications. In addition, the company offers customer support and training, and professional services. Okta, Inc. sells its products directly to customers through sales force, as well as through channel partners. The company was formerly known as Saasure, Inc. Okta, Inc. was founded in 2009 and is headquartered in San Francisco, California.</p>       <ul>
       <li>Robinhood Adjusted Rating: 67.47%</li>
       <li>Financial Modeling Prep Rating: 50.0%</li>
       <li>Finnhub Adjusted Rating: 80.687%</li>
       <li>Technical Analysis Aggregate Rating: neutral</li>
       <li>News Sentiment: 50.0%</li>
       <li>Social Media Sentiment: 14.887%</li>
       <li>Fair Stock Price Estimate: $237.45 (Stock is Undervalued)</li>
       <li>Insider Trading Transactions Rating: -32.0%</li>
       </ul>
</div></div></div>
</div>
</div>
<div id="footer">
<p>&copy; Jonathan Davies. All rights reserved. Design by <a href="http://templated.co" rel="nofollow">TEMPLATED</a>.</p>
</div>
</body>
</html>